Edition:
United States

Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

519.70INR
22 Jul 2016
Change (% chg)

Rs4.30 (+0.83%)
Prev Close
Rs515.40
Open
Rs519.45
Day's High
Rs522.30
Day's Low
Rs512.85
Volume
121,747
Avg. Vol
194,311
52-wk High
Rs748.00
52-wk Low
Rs458.25

Latest Key Developments (Source: Significant Developments)

Cipla Ltd asks government to revoke Novartis patents on respiratory drug - Reuters
Wednesday, 29 Oct 2014 08:00pm EDT 

Cipla Ltd:Says it had requested the Indian government to revoke five patents held by Novartis AG on respiratory drug Onbrez, to boost its access in the Indian market - Reuters.Alleged that Novartis has had patents on the drug since 2008/09, but did not make it in India, and instead imported a negligible quantity from Switzerland, leading to a shortage of supply.Says it has potential to manufacture adequate quantities of the drug and make the same available in the country.  Full Article

Cipla Medpro announces collaboration with generic pharmaceutical company
Thursday, 9 Oct 2014 12:02am EDT 

Cipla Ltd:Says Medpro Pharmaceutical (Pty) Ltd- a subsidiary company of Cipla Medpro has entered into a collaboration with TevaPharmaceutical(Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teve).Says the collaboration is restricted to the territory of South Africa.Says the collaboration is a sales and distribution whereby Cipla Medpro will exclusively market Teva's broad pharamaceutical product portfolio in South Africa.  Full Article

Cipla Ltd signs definitive agreement
Saturday, 4 Oct 2014 05:25am EDT 

Cipla Ltd:Signs a definitive agreement with its existing Iranian distributor for setting up a manufacturing facility in Iran.Says the total contribution from the company over the next 3 years will include machinery, equipment, technical know-how and is expected to be about 2.25 billion Indian rupees for a 75 pct stake.Says the proposed investment is subject to completion of certain conditions precedent and applicable regulatory approvals.  Full Article

Gilead Sciences Inc announces generic licensing agreements with Cipla Ltd and others
Monday, 15 Sep 2014 06:30am EDT 

Gilead Sciences Inc:Says it has signed non-exclusive licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C medicines in developing countries.Agreements allow the companies - Cadila Healthcare, Cipla , Hetero Labs ,Mylan Laboratories, Ranbaxy Laboratories, Sequent Scientific and Strides Arcolab - to manufacture sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 91 developing countries.Under the licensing agreements, the Indian companies receive a complete technology transfer of the Gilead manufacturing process to enable them to scale up production as quickly as possible.The licensees also set their own prices for the generic product they produce, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities.The licenses also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.  Full Article

Cipla Ltd announces commercial collaboration with S&D Pharma
Monday, 8 Sep 2014 06:02am EDT 

Cipla Ltd:Says a commercial collaboration with S&D Pharma in the Czech Republic and Slovakia.This collaboration will enable Cipla to focus on its core therapy areas, while S&D Pharma will be the key partner for generics.Cipla will be driving its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head.S&D Pharma will physically distribute all products, including respiratory products, and this portfolio will increase over the next few years.  Full Article

Cipla Ltd's Medispray Laboratories approved acquisition of two manufacturing undertakings
Friday, 5 Sep 2014 08:01am EDT 

Cipla Ltd:Says a subsidiary - Medispray Laboratories Pvt Ltd approved the acquisition of two manufacturing undertakings.The consideration for the above two transactions are 290 mln Indian Rupees and 719.3 mln Indian Rupees respectively.  Full Article